- Home
- CMPS vs SVRA Comparison
CMPS vs SVRA Comparison
Compare CMPS & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMPS | SVRA |
|---|---|---|
| Founded | 2020 | 2007 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2020 | 2009 |
Fundamental Metrics
Financial Performance| Metric | CMPS | SVRA |
|---|---|---|
| Price | $9.50 | $5.33 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 9 |
| Target Price | ★ $25.38 | $7.33 |
| AVG Volume (30 Days) | ★ 5.1M | 1.2M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $430.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.25 | $1.89 |
| 52 Week High | $10.21 | $7.01 |
Technical Indicators
Market Signals| Indicator | CMPS | SVRA |
|---|---|---|
| Relative Strength Index (RSI) | 68.21 | 48.75 |
| Support Level | $4.56 | $5.10 |
| Resistance Level | $10.21 | $6.15 |
| Average True Range (ATR) | 0.79 | 0.28 |
| MACD | 0.14 | -0.03 |
| Stochastic Oscillator | 86.06 | 34.71 |
Price Performance
Historical ComparisonAbout CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
About SVRA Savara Inc.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).